Consistent with the activation of mTOR in patients experiencing an asthma attack, we observed significantly higher levels of p-PI3K, p-Akt, p-mTOR, and p-p70S6k in asthmatic mice than in the control and budenoside treatment groups (Fig. 5a and b). The gene discussed is RPS6KB1; the disease is asthma.